Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment

NCT07671755 | Completed

• 1 other identifier: IRB-000154/SMBBIT/Approval/202
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate clinical outcomes of colistin versus colistin in combination with cefoperazone-sulbactam for patients with MDR-AB VAP treatment.

Conditions

Clinical Response; Radiological Response

Keywords

multidrug-resistant Acinetobacter baumannii; ventilator-associated pneumonia; intensive care unit

Outcome Measures

Primary Outcomes (1)

• Clinical response

  Clinical response was defined as observable improvement in the patient's clinical signs/symptoms, including absence of fever (temp\<38ºC) for three consecutive days or more, and decreasing amount and purulence of tracheal secretions

  within one week

Secondary Outcomes (1)

• Radiological response

  within one week

Study Arms (2)

Intervention

EXPERIMENTAL

Intervention group received colistin plus cefoperazone-sulbactam combination group.

Drug: colistin plus cefoperazone-sulbactam combination group

Comparator

ACTIVE COMPARATOR

Comparator group received colistin monotherapy

Drug: Colistin

Interventions

colistin plus cefoperazone-sulbactam combination group DRUG

Combination therapy

Intervention

Colistin DRUG

Monotherapy

Comparator

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with a diagnosis of VAP due to A. baumannii

You may not qualify if:

• patients who had polymicrobial VAP
• Patients with pre-existing severe renal failure and/or abnormal liver function tests
• Patients allergic to colistin or cefoperazone-sulbactam

Sponsors & Collaborators

• Shaheed Mohtarma Benazir Bhutto Institue of Trauma: lead

Study Sites (1)

Shaheed Mohtarma Benazir Bhutto Institue of Trauma

Karachi, Pakistan

Location

Related Links

• Colistin versus Colistin Combined with Ampicillin-Sulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia Treatment: An Open-label Prospective Study
• Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia

MeSH Terms

Conditions

Pneumonia, Ventilator-Associated

Interventions

Colistin

Condition Hierarchy (Ancestors)

Healthcare-Associated Pneumonia; Cross Infection; Infections; Pneumonia; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases; Iatrogenic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Polymyxins; Peptides, Cyclic; Macrocyclic Compounds; Polycyclic Compounds; Lipopeptides; Lipids; Antimicrobial Cationic Peptides; Peptides; Amino Acids, Peptides, and Proteins; Antimicrobial Peptides; Pore Forming Cytotoxic Proteins; Membrane Proteins; Proteins

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 22, 2026
• First Posted: June 26, 2026
• Study Start: February 1, 2025
• Primary Completion: December 30, 2025
• Study Completion: April 30, 2026
• Last Updated: June 26, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)